PMID- 33725855
OWN - NLM
STAT- MEDLINE
DCOM- 20210329
LR  - 20230103
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 100
IP  - 10
DP  - 2021 Mar 12
TI  - Prevalence and risk factor analysis for the nonalcoholic fatty liver disease in 
      patients with type 2 diabetes mellitus.
PG  - e24940
LID - 10.1097/MD.0000000000024940 [doi]
LID - e24940
AB  - Although non-alcoholic fatty liver disease (NAFLD) is strongly associated with 
      type 2 diabetes mellitus (T2DM), the diagnosis of NAFLD for T2DM patients remains 
      a challenge.This study aimed to investigate the prevalence and risk factors for 
      the NAFLD in T2DM outpatients.This is a retrospective, cross-sectional study that 
      included 2405 T2DM patients treated and admitted for glucose control into the 
      Endocrinology Department of our hospital from April 2017 to March 2019. Using 
      strict exclusion criteria, the target patients were screened and divided into two 
      groups: NAFLD patients (study group) and non-NAFLD patients (control group). 
      Subsequently, 34 factors were compared between the two groups. Furthermore, 
      multivariate analysis of the NAFLD risk factors was performed using logistic 
      regression. Finally, the diagnostic significance of individual biochemical 
      predictors, as well as the combined predictive indicator (CPI), for NAFLD was 
      estimated using receiver operating characteristic (ROC) curve analysis.In this 
      study, the overall prevalence of NAFLD in T2DM patients was 58.67%. Of the target 
      patients, 17 factors were identified by univariate analysis to be associated with 
      NAFLD, and 8 factors were found to be significant predictors for NAFLD using 
      binary logistic regression modeling. Furthermore, the CPI and C-Peptide represent 
      high diagnostic value for NAFLD in T2DM patients.This study provides a more 
      comprehensive risk factor analysis for NAFLD in T2DM patients. These data can be 
      used to provide timely diagnosis and effective management of NAFLD.
CI  - Copyright (c) 2021 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Zhou, Qiumei
AU  - Zhou Q
AD  - Experimental Center of Clinical Research, The First Affiliated Hospital of Anhui 
      University of Chinese Medicine.
FAU - Wang, Yulong
AU  - Wang Y
AD  - Anhui Provincial Key Laboratory of Microbial Pest Control, Anhui Agricultural 
      University.
FAU - Wang, Jiajia
AU  - Wang J
AD  - Department of Ultrasonic Medicine.
FAU - Liu, Yating
AU  - Liu Y
AD  - Department of Laboratory Medicine, The First Affiliated Hospital of Anhui 
      University of Chinese Medicine, Hefei.
FAU - Qi, Dehui
AU  - Qi D
AD  - Zhengzhou Antu Biological Engineering Co. LTD.
FAU - Yao, Wei
AU  - Yao W
AD  - Experimental Center of Clinical Research, The First Affiliated Hospital of Anhui 
      University of Chinese Medicine.
FAU - Jiang, Hui
AU  - Jiang H
AD  - Experimental Center of Clinical Research, The First Affiliated Hospital of Anhui 
      University of Chinese Medicine.
FAU - Li, Tingting
AU  - Li T
AD  - Department of Laboratory Medicine, The First Affiliated Hospital of Anhui 
      University of Chinese Medicine, Hefei.
FAU - Huang, Kaiquan
AU  - Huang K
AD  - Experimental Center of Clinical Research, The First Affiliated Hospital of Anhui 
      University of Chinese Medicine.
FAU - Zhang, Wancun
AU  - Zhang W
AD  - Department of Pediatric Oncology Surgery, Henan Provincial Key Laboratory of 
      Children's Genetics and Metabolic Diseases, Children's Hospital Affiliated to 
      Zhengzhou University, Zhengzhou, China.
FAU - Huo, Xingxing
AU  - Huo X
AUID- ORCID: 0000-0002-9506-1361
AD  - Experimental Center of Clinical Research, The First Affiliated Hospital of Anhui 
      University of Chinese Medicine.
LA  - eng
GR  - 1808085QH250/Natural Science Foundation of Anhui Province/
GR  - 202102310068/Scientific and technological projects of Henan Province/
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Adult
MH  - Aged
MH  - Cross-Sectional Studies
MH  - Diabetes Mellitus, Type 2/*complications
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Non-alcoholic Fatty Liver Disease/diagnosis/*epidemiology/etiology
MH  - Prevalence
MH  - Retrospective Studies
MH  - Risk Assessment/statistics & numerical data
MH  - Risk Factors
PMC - PMC7969325
COIS- The authors have no conflict of interest to disclose.
EDAT- 2021/03/18 06:00
MHDA- 2021/03/30 06:00
PMCR- 2021/03/12
CRDT- 2021/03/17 01:08
PHST- 2020/08/12 00:00 [received]
PHST- 2020/11/30 00:00 [accepted]
PHST- 2021/03/17 01:08 [entrez]
PHST- 2021/03/18 06:00 [pubmed]
PHST- 2021/03/30 06:00 [medline]
PHST- 2021/03/12 00:00 [pmc-release]
AID - 00005792-202103120-00049 [pii]
AID - MD-D-20-07609 [pii]
AID - 10.1097/MD.0000000000024940 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2021 Mar 12;100(10):e24940. doi: 
      10.1097/MD.0000000000024940.